Abbott Laboratories vs. Pacira BioSciences, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | PCRX | |
|---|---|---|
| Market Cap | $191.92 billion | $944.73 million |
| Revenue (TTM) | $46.59 billion | $746.16 million |
| Net Income (TTM) | $5.42 billion | $14.64 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | PCRX | |
|---|---|---|
| P/E Ratio | 36.00 | 65.71 |
| Price / Book | 3.71 | 1.41 |
| Price / Sales | 4.12 | 1.27 |
PCRX leads on 2 of 3 valuation factors.
Profitability
| ABT | PCRX | |
|---|---|---|
| Net Margin | 11.65% | 1.96% |
| Return on Equity | 10.48% | 2.18% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | PCRX | |
|---|---|---|
| Dividend Yield | 2.27% | — |
| Payout Ratio | 81.55 | — |
ABT and PCRX split the dividend factors evenly.
Risk & Sentiment
| ABT | PCRX | |
|---|---|---|
| Short Interest | 0.57% | 9.32% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, PCRX overview, PCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.